RxDoctor Payments Data

Gregory Deines, DO

Endocrinology, Diabetes & Metabolism · Grand Rapids, MINPI 1427098532

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (59.2%), food and beverage and education — rather than concentrated in one kind of arrangement. 10 manufacturers reported payments, led by Lilly USA, LLC at 29.6% of the total. Reporting peaked in 2020 at $5,315 and has fallen 78.3% since, to $1,156 in 2025.

$8,778in general payments, 2019–2025

Across 49 payments — averaging $179.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$3K
  • Eli Lilly$3K
  • Medtronic$2K
  • Boehringer Ingelheim$479
  • Sequel Med Tech, LLC$272
  • Dexcom, Inc.$194
  • plus $406 from 4 others

What the payments were for

  • Consulting fees$5,20059%
  • Food & beverage$3,55941%
  • Education$190%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,778 in reported general payments places this provider in the 75th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.

See all endocrinology, diabetes & metabolism providers in Michigan

Medicare billing

Part B allowed, 2024
$24,688
Medicare patients
149
Services billed
404

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide154$203,774
TrulicityDulaglutide143$183,082
JardianceEmpagliflozin104$114,392
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog47$40,065
FarxigaDapagliflozin Propanediol30$33,653
OzempicSemaglutide29$31,334
Humalog Kwikpen U-100Insulin Lispro88$27,639
HumalogInsulin Lispro69$27,534
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/734$24,028
LyumjevInsulin Lispro-Aabc14$23,030
Fiasp FlextouchInsulin Aspart (Niacinamide)15$19,610
Novolog FlexpenInsulin Aspart53$19,448
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog37$18,826
Lantus SolostarInsulin Glargine,hum.Rec.Anlog123$17,019
NovologInsulin Aspart37$16,494

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humalog, Lyumjev, Insulin Lispro$2,600$439,779405 claims
Boehringer IngelheimJardiance$479$114,392104 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.

Other endocrinology, diabetes & metabolism in Grand Rapids

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →